Mirum Pharmaceuticals (MIRM) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.42
- Estimate
- -$0.41
- Surprise
- -0.3%
- Revenue (period 2026-09-30)
- $185.7M
- Score at report (before → after)
- 6.3 → 6.3/10
Revenue source: xbrl.
How the report landed
Mirum Pharmaceuticals (MIRM) reported a wider loss than forecast — adjusted EPS of -$0.42 against the -$0.41 estimate (a 0.3% shortfall). TrendMatrix's engine moved from Hold (6.3/10) to Sell at 6.3/10 after the report.
Coverage in the report window
- Mirum Pharmaceuticals Q3 EPS $(0.87) Misses $(0.51) Estimate, Sales $185.721M Beat $178.078M Estimate — benzinga, 2026-11-03
Where TrendMatrix's rating stands now
TrendMatrix currently rates MIRM Sell at 6.2/10.
0 of the last 4 quarters beat the estimate; this quarter's -0.3% surprise compares with a -130.5% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Supplier: one specialty pharmacy
- Consecutive earnings misses (4)
- Value-trap signals (2/5): Margin compression (op margin -14.8%), Material insider selling (9 sells, 0.19% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $87.03
- Price target
- $133.48
- Stop
- $80.99
- Upside to target
- +53.4%
- Reward-to-risk
- 5.3:1
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
MIRM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.65B
- P/E (fwd)
- -511.9
- 52-week range
- $63.23–$130.00
- Off 52-week high
- 33.1%
- RSI (14)
- 65
- Volume vs avg
- 0.93×
- Score today
- 6.2/10